Finally, overexpression of MET is associated with the upregulation of programmed death-ligand 1 (PD-L1) in pre-clinical models and sunitinib-treated metastatic RCC patients, implying its possible role in regulating immune checkpoint therapy in ccRCC [163,164] (Figure 3). This evidence concerns the gene MET and nonpapillary renal cell carcinoma.